Process for the Production of Fused, Tricyclic Sulfonamides

A method comprising:

• (ii) contacting a first compound having a structure according to Formula (X):
• wherein
• M is selected from Li and MgX, wherein X is halogen;
• n is an integer selected from 0 to 4;
• N1 and N2 are nitrogen atoms of a pyrazole ring;
• X1 is F, Cl, Br, I, tosylate or mesylate;
• R3 is an amino protecting group covalently bonded to N1 or N2;
• and
• R1 is a member independently selected from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CN, halogen, OR4, SR4, NR4R5, C(O)R6, C(O)NR4R5, OC(O)NR4R5, C(O)OR4, NR7C(O)R6, NR7C(O)OR4, NR7C(O)NR4R5, NR7C(S)NR4R5, NR7S(O)2R6, S(O)2NR4R5, S(O)R6 and S(O)2R6,
• wherein
• each of the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• R4, R5, and R7 are independently selected from H, acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R4 and R5, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• R6 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl,
• wherein
• each R14, each R15, and each R17 is independently selected from H, acyl, C1-C6-alkyl, C1-C6 haloalkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R14 and R15, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• each R16 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl,
• with a sulfinylimine having a structure according to Formula (XI):
• wherein
• R2 is selected from H, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, each optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16, and S(O)2R16;
• and
• R10a is selected from alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, each optionally substituted with from 1 to 5 substituents selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• wherein
• thereby forming a second compound having a structure according to Formula (XII):
• or a salt or solvate thereof.

A method comprising:

• (j) contacting a first compound having a structure according to Formula (Xm):
• or a salt or solvate thereof,
• wherein
• M is Li or MgX, wherein X is Cl, Br or I;
• X1 is F, Cl or Br;
• p is 0 or 1;
• and
• R3 is an amino protecting group,
• with a sulfinylimine having a structure according to Formula (XIa):
• wherein R10a is branched (C3-C8)alkyl, branched 3- to 8-membered heteroalkyl, (C3-C10)cycloalkyl, 3- to 6-membered heterocycloalkyl, aryl, and 5- or 6-membered heteroaryl,
• under reaction conditions sufficient to form a second compound having a structure according to Formula (XIIa):
• or a salt or solvate thereof;
• and
• (ii) removing a sulfinyl moiety from the second compound of Formula (XIIa), thereby forming a third compound having a structure according to Formula (XIIIa):
• or a salt or solvate thereof.

A method of affecting an intra-molecular cyclization, the method comprising:

• (i) contacting a first molecule having a structure according to Formula (III):
• or a salt or solvate thereof,
• wherein
• r is an integer selected from 2 to 4;
• m is an integer selected from 0 to 2, provided that the sum of m and r is not greater than 4;
• N1 and N2 are nitrogen atoms of a pyrazole ring;
• X1 is F, Cl, Br, I, tosylate or mesylate;
• X2 is F, Cl or Br;
• R1 is a member independently selected from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CN, halogen, OR4, SR4, NR4R5, C(O)R6, C(O)NR4R5, OC(O)NR4R5, C(O)OR4, NR7C(O)R6, NR7C(O)OR4, NR7C(O)NR4R5, NR7C(S)NR4R5, NR7S(O)2R6, S(O)2NR4R5, S(O)R6 and S(O)2R6,
• wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with from 1 to 3 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16;
• R4, R5, and R7 are independently selected from H, acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R4 and R5, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• R6 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl;
• R2 is a member selected from H, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16, and S(O)2R16;
• R3 is an amino protecting group covalently bonded to N1 or N2 of the pyrazole;
• and
• Cy is a member selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• wherein
• each R14, each R15, and each R17 is independently selected from H, acyl, C1-C6-alkyl, C1-C6 haloalkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R14 and R15, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• each R16 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl,
• with a base, in the absence of a metal catalyst, under reaction conditions sufficient to form a second molecule having a structure according to Formula (IV):
• or a salt or solvate thereof, wherein Cy, m, r, X2, R1, R2 and R3 are defined as for Formula (I).

A compound having a structure according to Formula (XX):

• or a salt or solvate thereof,
• wherein
• N1 and N2 are nitrogen atoms of a pyrazole ring;
• I is iodine;
• X1 is halogen;
• R3 is an amino protecting group covalently bonded to N1 or N2 of the pyrazole ring;
• m is an integer selected from 0 to 3;
• and
• each R1 is a member independently selected from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CN, halogen, OR4, SR4, NR4R5, C(O)R6, C(O)NR4R5, OC(O)NR4R5, C(O)OR4, NR7C(O)R6, NR7C(O)OR4, NR7C(O)NR4R5, NR7C(S)NR4R5, NR7S(O)2R6, S(O)2NR4R5, S(O)R6 and S(O)2R6,
• wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• wherein
• R14, R15, and R17 are independently selected from H, acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R14 and R15, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• R16 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl;
• R4, R5, and R7 are independently selected from H, acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R4 and R5, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• R6 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl.

A compound having a structure according to Formula (XXII):

• or a salt or solvate thereof,
• wherein
• X1 is halogen;
• R3 is an amino protecting group;
• m is an integer selected from 0 to 3;
• each R1 is a member independently selected from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CN, halogen, OR4, SR4, NR4R5, C(O)R6, C(O)NR4R5, OC(O)NR4R5, C(O)OR4, NR7C(O)R6, NR7C(O)OR4, NR7C(O)NR4R5, NR7C(S)NR4R5, NR7S(O)2R6, S(O)2NR4R5, S(O)R6 and S(O)2R6,
• wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• R4, R5, and R7 are independently selected from H, acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R4 and R5, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• R6 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl.
• R2 is selected from H, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, each optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16, with the proviso that R2 is other than carboxyl or carboxyl-substituted C1-C3-alkyl;
• R40 is selected from H, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, S(O)R10a, and S(O)2Cy,
• wherein
• each of the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl of R40 is optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16;
• R10a is selected from alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, each optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16;
• and
• Cy is a member selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted with from 1 to 5 substituents independently selected from C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, C1-C6-haloalkyl, 2- to 6-membered heteroalkyl, C3-C6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR14, SR14, NR14R15, C(O)R16, C(O)NR14R15, OC(O)NR14R15, C(O)OR14, NR17C(O)R16, NR17C(O)OR14, NR17C(O)NR14R15, NR17C(S)NR14R15, NR17S(O)2R16, S(O)2NR14R15, S(O)R16 and S(O)2R16,
• wherein
• each R14, each R15, and each R17 is independently selected from H, acyl, C1-C6-alkyl, C1-C6 haloalkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R14 and R15, together with the nitrogen atom to which they are bound, are optionally joined to form a 5- to 7-membered heterocyclic ring;
• and
• each R16 is selected from acyl, C1-C6-alkyl, C1-C6-alkenyl, C1-C6-alkynyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl.

A compound selected from:

• 5-(2-bromo-5-fluorophenyl)-1-tert-butyl-4-iodo-1H-pyrazole;
• 5-(2-bromo-4-fluorophenyl)-1-tert-butyl-4-iodo-1H-pyrazole;
• 5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-4-iodo-1H-pyrazole;
• and
• 1-tert-butyl-4-iodo-5-(2,4,5-trifluorophenyl)-1H-pyrazole;
• (5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• (5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• (5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)-methanamine;
• (1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• (1R)- (5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• (1R)- (5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• (1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• and
• (1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methanamine;
• N-((5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((1R)-(5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((1R)-(5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• and
• N-((1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methylpropane-2-sulfinamide;
• N-((5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)-methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((1R)-(5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((1R)-(5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-4-(trifluoromethyl)benzenesulfonamide;
• N-((1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide;
• N-((1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-6-(trifluoromethyl)pyridine-3-sulfonamide,
• N-((1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-3-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-3-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-3-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-3-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(1-tert-butyl-5-(2,4,5-trifluorophenyl)-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4,5-difluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• N-((1R)-(5-(2-bromo-4-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methoxy-4-(trifluoromethyl)benzenesulfonamide;
• and
• N-((1R)-(5-(2-bromo-5-fluorophenyl)-1-tert-butyl-1H-pyrazol-4-yl)(cyclopropyl)methyl)-2-methoxy-4-(trifluoromethyl)benzenesulfonamide,
• or a salt, solvate, tautomer or mixture of tautomers thereof.